06.16.22
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they offer the potential for the accelerated approval of patient-centric medicines.
Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
You can obtain detailed information about the use of cookies on our website by clicking on "More information”.
Copyright © 2024 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.